Abstract
Vortioxetine is a modern antidepressant with a broad receptor profile. In the US (Food and Drug Administration, FDA) and in Europe (European Medicines Agency, EMA) vortioxetine has been registered for the treatment of major depressive episodes in adults. Currently, however, trials are underway to extend the therapeutic indications for this drug. Duloxetine is a drug from the group of serotonin and noradrenaline reuptake inhibitors. Its registered indications include: major depressive disorders, diabetic neuropathic pain and generalized anxiety disorder. Both duloxetine and vortioxetine are registered for the treatment of adults.